Myopia And Presbyopia Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Myopia Treatment Type, By Presbyopia Treatment Type, By Region and Competition, 2020-2030F

Global Myopia and Presbyopia Treatment Market was valued at USD 20.27 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 8.28% through 2030. Myopia, or nearsightedness, is a refractive error in which distant objects appear blurred due to improper light focus caused by an elongated eyeball or an excessively curved cornea. This condition is effectively corrected using concave lenses, which refocus light onto the retina. Myopia is denoted by a negative diopter value in eyeglass prescriptions. Presbyopia, by contrast, is an age-related decline in near-vision acuity resulting from reduced elasticity of the eye's crystalline lens. Positive-powered reading glasses are the most common solution, available both over the counter and by prescription.

The ophthalmology sector has witnessed significant technological advancements that have enhanced the treatment landscape for both conditions. Cutting-edge surgical interventions, innovative contact lens designs, and advanced diagnostic tools have not only broadened patient care options but have also driven robust market growth. For myopia, pharmaceutical solutions such as atropine eye drops are emerging as viable control measures, attracting considerable attention and investment. Rising patient awareness regarding vision health, coupled with an increased emphasis on regular eye examinations, has further accelerated demand. Public health initiatives led by governments and NGOs play a critical role in promoting early diagnosis and intervention.

The aging global population is a significant factor propelling the presbyopia treatment market, with a growing need for solutions tailored to age-related vision deterioration. These demographic trends, combined with ongoing innovation in the field, present substantial opportunities for growth and expansion within the vision care industry.

Key Market Drivers

Technological Advancements

Low-dose atropine eye drops have shown promise in slowing the progression of myopia in children. This pharmaceutical treatment has gained attention as an alternative to traditional corrective lenses. Ortho-K involves wearing specially designed contact lenses overnight to reshape the cornea. Technological advancements have led to improved lens designs, enhancing safety and efficacy. Laser-assisted refractive surgeries like LASIK and PRK have benefited from femtosecond lasers. These lasers enable more precise corneal reshaping, reducing recovery times and improving outcomes. Digital lens manufacturing has improved the design and performance of multifocal and progressive eyeglass lenses for presbyopia correction. These lenses provide a more natural and seamless transition between different vision zones.

Custom wavefront-guided treatments are being used in refractive surgeries to address higher-order aberrations, leading to better visual quality, especially in low-light conditions. Silicone hydrogel contact lenses offer improved comfort, breathability, and extended wear options for myopia and presbyopia correction. Phakic Intraocular Lenses, used in surgical myopia correction, have seen advancements in lens materials, design, and implantation techniques, enhancing safety and outcomes. Extended Depth of Focus (EDOF) intraocular lenses are designed to provide clear vision at multiple distances without the need for reading glasses. Technological improvements in these lenses have enhanced visual outcomes.

Telemedicine has become more prevalent in eye care. Digital refraction tools enable remote vision assessments and prescription updates for myopia and presbyopia patients. AI algorithms can assist in diagnosing myopia and presbyopia and predict disease progression, helping clinicians make more informed treatment decisions. Mobile apps and software have been developed to educate individuals about myopia and presbyopia and to offer vision training and monitoring programs. Gene therapy research holds promise for the treatment of myopia by targeting genetic factors associated with the condition. This factor will help in the development of the Global Myopia and Presbyopia Treatment Market.

Rising Aging Population

Presbyopia is an age-related vision condition that typically begins to affect individuals in their 40s. The global demographic landscape is undergoing a significant shift, with the population aged 65 and older projected to more than double from 761 million in 2021 to 1.6 billion by 2050. Even more pronounced is the rapid growth of the 80+ age group, which is expanding at an accelerated pace. This irreversible trend of population aging is reshaping industries, creating opportunities for businesses to cater to the evolving needs of an older demographic, particularly in healthcare, financial services, and age-friendly technologies. As people age, the natural loss of elasticity in the eye's crystalline lens makes it challenging to focus on close objects. This results in the need for reading glasses or other presbyopia treatments. Therefore, an aging population directly leads to a higher prevalence of presbyopia, which drives the demand for presbyopia treatment options. Myopia, or nearsightedness, often develops during childhood and adolescence but can continue to progress into adulthood. With age, the progression of myopia may result in worsening vision, making it necessary for individuals to seek myopia control and treatment options. As the aging population includes individuals who may have had myopia from a young age, the need for myopia treatment persists.

Some individuals may develop both myopia and presbyopia as they age. These dual vision conditions require comprehensive treatment, often involving prescription eyeglasses or contact lenses to address both nearsightedness and age-related farsightedness. Clear vision is essential for maintaining a high quality of life and remaining productive as people age. Correcting myopia and presbyopia ensures that individuals can continue to perform daily tasks, work, and enjoy recreational activities. Aging individuals are more likely to seek advanced treatment options for vision correction, benefiting from technological advancements in eyeglasses, contact lenses, intraocular lenses, and surgical procedures. In April 2022, the United Nations estimated the global population at 7.9 billion. In 2015, approximately 1.8 billion individuals were identified as presbyopic, a figure projected to rise to 2.1 billion by 2020-representing 26% of the global population. In the United States, presbyopia prevalence among adults aged 45 and older ranges from 83.0% to 88.9%, with an estimated 123 million presbyopes nationwide in 2020. These figures underscore the substantial and growing demand for presbyopia-related treatments and solutions both globally and domestically.

Aging populations typically have more regular healthcare check-ups, including eye examinations, which can lead to the diagnosis of myopia and presbyopia. This promotes the early detection and management of these conditions, further driving the demand for treatment. As the aging population often possesses greater financial stability and access to healthcare, they are more inclined to invest in effective vision correction solutions. Older individuals may also be more motivated to address vision issues early to prevent further complications and ensure that age-related eye diseases, like cataracts, are managed appropriately. Public health campaigns and educational efforts targeting the aging population raise awareness about the importance of regular eye check-ups and available treatments, further driving demand. This factor will pace up the demand of the Global Myopia and Presbyopia Treatment Market.

Increasing Pharmaceutical Innovations

Pharmaceutical innovations, such as low-dose atropine eye drops and other myopia control agents, have shown promise in slowing the progression of myopia, especially in children. These treatments are increasingly sought after by parents and eyecare professionals who wish to manage myopia effectively. Ongoing research and development efforts have focused on pharmaceutical eye drops designed to improve near vision in individuals with presbyopia. These innovations offer potential alternatives to traditional reading glasses or multifocal contact lenses. Pharmaceutical treatments can offer more convenient and patient-friendly solutions, especially for individuals who may be averse to wearing corrective lenses. The ease of using eye drops or pharmaceutical interventions can drive demand, particularly among those with presbyopia. Pharmaceutical treatments for myopia control are appealing to parents who want to intervene early to prevent their children's myopia from worsening. As the understanding of the long-term risks associated with high myopia grows, the demand for pharmaceutical interventions also increases. Our analysis of biomedical research funding leveraged data from the World RePORT database as of October 2022. The dataset encompassed 650,875 grants distributed to 23,005 research organizations across 188 countries. Notably, the funding information was sourced from 14 contributors, all representing high-income countries (HICs). This highlights the significant role of HIC-based funders in shaping the global biomedical research landscape, with extensive reach and impact across diverse regions.

Some patients prefer pharmaceutical interventions over surgical procedures for vision correction. Innovations in pharmaceuticals offer non-invasive or minimally invasive alternatives, attracting individuals who seek less invasive treatment options. Advances in pharmacogenomics and genetic testing can enable more personalized pharmaceutical treatments, tailoring interventions to an individual's genetic predisposition for myopia and presbyopia. Ongoing research explores combination therapies that incorporate pharmaceutical interventions with other treatment modalities, such as contact lenses or vision training programs. These integrated approaches offer a comprehensive solution for myopia and presbyopia.

Pharmaceutical companies continue to invest in research and development efforts focused on myopia and presbyopia treatments. This investment results in a broader range of treatment options, driving demand for these innovations. As pharmaceutical treatments for myopia control and presbyopia receive regulatory approvals, they become more widely accepted and adopted by eyecare professionals and patients. Educational campaigns and public awareness efforts by pharmaceutical companies and healthcare organizations inform consumers about the availability and benefits of pharmaceutical innovations, increasing demand. This factor will accelerate the demand of the Global Myopia and Presbyopia Treatment Market.

Key Market Challenges

Resistance to Surgery

Many individuals be afraid and apprehension about undergoing surgical procedures, especially when it involves their eyes. Concerns about pain, complications, and potential side effects can deter patients from considering surgery as a treatment option. Patients often prefer non-invasive or minimally invasive treatment options over surgery. Corrective eyewear, such as eyeglasses and contact lenses, are non-invasive and do not involve any surgical risk. Corrective lenses offer convenience and flexibility, allowing patients to easily remove or adjust them as needed. Surgery, on the other hand, may require a more significant commitment of time and effort. All surgical procedures carry inherent risks, including infection, inflammation, or complications that can affect vision. The potential risks and uncertainties associated with surgery can be a deterrent for some patients. Surgery for myopia and presbyopia can be expensive, and not all patients can afford it. Corrective eyewear or pharmaceutical treatments may be more cost-effective alternatives. Patients may be concerned about the long-term impact of surgical procedures, such as the potential need for follow-up surgeries or adjustments. They may prefer solutions that provide greater long-term stability. Some individuals, particularly older patients, or those with underlying health conditions, may not be suitable candidates for surgical procedures. This limits their treatment options and may lead to resistance to surgery.

Safety and Efficacy Concerns

Patients may be reluctant to try new treatments or technologies due to concerns about their safety and effectiveness. This reluctance can delay or limit the adoption of innovative solutions. Some treatment options, especially emerging technologies, may lack a well-established track record for long-term safety and efficacy. Patients may be hesitant to try these treatments without assurance of positive outcomes. Surgical procedures and certain treatments carry a risk of complications, including infection, inflammation, or post-operative issues. Patients are concerned about potential adverse events and the impact on their vision. For patients with myopia or presbyopia, the long-term effectiveness of treatments is a significant concern. They want assurance that the treatment will provide sustained benefits over time. Ensuring the safety and efficacy of new treatments and devices is a complex process that requires compliance with regulatory standards. Some treatments may face delays or challenges in gaining regulatory approval. Patient responses to treatments can vary, and there is no one-size-fits-all solution. This can lead to concerns about whether a treatment will work effectively for an individual. Emerging treatments may have limited clinical data available, making it difficult for patients to assess their safety and efficacy based on established evidence. Patients have high expectations when it comes to their vision, and they want treatments to meet or exceed those expectations. If treatments fall short, patient dissatisfaction and concerns about efficacy can arise.

Key Market Trends

Personalized Medicine

Personalized medicine considers the genetic factors that may contribute to myopia or presbyopia. Understanding an individual's genetic predisposition can help clinicians make more precise treatment decisions. Pharmacogenomic research focuses on how genetic variations can affect a person's response to medications. This approach can guide the choice of pharmaceutical treatments and their dosages based on a patient's genetic profile. Rather than a one-size-fits-all approach, personalized medicine allows for the creation of customized treatment plans that address the unique needs and characteristics of each patient. For myopia, personalized medicine can involve the selection of specific interventions, such as atropine eye drops or orthokeratology, based on a patient's age, rate of myopia progression, and genetic factors that may influence their response to treatment. In the case of presbyopia, personalized medicine considers factors such as the patient's age, visual demands, and the presence of any concurrent vision conditions when recommending treatments like progressive eyeglasses, multifocal contact lenses, or pharmaceutical options. Lifestyle factors, such as screen time, outdoor activities, and near-work habits, can impact myopia progression. Personalized medicine may involve recommending lifestyle changes or interventions that suit the patient's specific habits and needs. Personalized medicine also includes regular monitoring and adjustments to the treatment plan as needed. Clinicians can adapt treatments based on how an individual responds over time.

Segmental Insights

Presbyopia Treatment Type Insights

In 2024, the Global Myopia and Presbyopia Treatment Market largest share was held by Prescription segment in the forecast period and is predicted to continue expanding over the coming years. Presbyopia is an age-related vision problem that affects nearly everyone as they get older. It is a natural part of the aging process and typically begins to impact individuals in their 40s. As a result, there is a large and growing market for presbyopia treatment. Eyeglasses with prescription lenses are a primary and highly effective treatment for presbyopia. Multifocal or progressive addition lenses, commonly prescribed for presbyopia, provide clear vision for both near and distance tasks, and they are well-accepted by patients. Eyecare professionals can prescribe customized prescription lenses that precisely address the individual visual needs of patients. This level of customization ensures accurate and comfortable vision correction for presbyopia. Many individuals prefer prescription eyeglasses as a treatment for presbyopia due to their simplicity, comfort, and immediate effectiveness. Corrective lenses offer clear vision without the need for invasive procedures. Prescription eyewear, especially reading glasses and multifocal lenses, is widely accessible and commonly used by individuals experiencing presbyopia. People are familiar with these options and often turn to them for vision correction. Health insurance plans in many regions typically cover the cost of prescription eyeglasses for presbyopia. This makes it an affordable and practical choice for patients.

Regional Insights

The North America region dominates the Global Myopia And Presbyopia Treatment Market in 2024. North America, particularly the United States and Canada, boasts a well-developed and advanced healthcare infrastructure. This infrastructure includes a high density of eye care professionals, modern medical facilities, and access to the latest medical technologies and treatments. The region is a hub for innovation and technological advancements in the healthcare and ophthalmology sectors. Research and development of new treatments, surgical procedures, and diagnostic tools for myopia and presbyopia are prevalent in North America. North America typically has higher healthcare spending per capita compared to many other regions. This allows for greater investment in research, development, and adoption of new treatments and technologies. The presence of prominent pharmaceutical companies and biotech firms in North America facilitates the development of pharmaceutical treatments for myopia and presbyopia. This includes the creation of eye drops and medications aimed at controlling myopia progression.

Key Market Players

• Ziemer Ophthalmic Systems AG
• NIDEK CO., LTD.
• Johnson & Johnson Vision
• EssilorLuxottica.
• ZEISS Group
• Alcon Vision LLC
• Bausch + Lomb Corporation
• Haag-Streit UK
• Topcon Corporation

Report Scope:

In this report, the Global Myopia and Presbyopia Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Myopia And Presbyopia Treatment Market, By Myopia Treatment Type:

• Corrective
• Surgical
• Drugs

Myopia And Presbyopia Treatment Market, By Presbyopia Treatment Type:

• Prescription
• Contact Lenses
• Intraocular Lenses
• Refractive Surgery

Myopia And Presbyopia Treatment Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Myopia And Presbyopia Treatment Market.

Available Customizations:

Global Myopia And Presbyopia Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).